PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PEPG PepGen Inc.

Pre-Mkt 05-04 07:01:15 EDT

1.75

+0.11

+6.71%

盘前1.77

+0.02+1.14%

07:00 EDT

High1.80	Low1.64	Vol1.87M
Open1.64	D1 Closing1.64	Amplitude9.76%
Mkt Cap120.95M	Tradable Cap80.11M	Total Shares69.12M
T/O3.27M	T/O Rate4.09%	Tradable Shares45.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PEPG","market":"US","secType":"STK","nameCN":"PepGen Inc.","latestPrice":1.75,"timestamp":1777665600000,"preClose":1.64,"halted":0,"volume":1872329,"hourTrading":{"tag":"盘前","latestPrice":1.77,"preClose":1.75,"latestTime":"07:00 EDT","volume":30001,"amount":53101.7730001,"timestamp":1777892438558,"change":0.02,"changeRate":0.011429,"amplitude":0.001257},"delay":0,"changeRate":0.06707317073170738,"floatShares":45776899,"shares":69115292,"eps":-2.123428,"marketStatus":"Pre-Mkt","change":0.11,"latestTime":"05-04 07:01:15 EDT","open":1.64,"high":1.8,"low":1.64,"amount":3265991.2869301,"amplitude":0.097561,"askPrice":1.8,"askSize":60,"bidPrice":1.56,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.123428,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777901400000},"marketStatusCode":1,"adr":0,"listingDate":1651809600000,"exchange":"NASDAQ","adjPreClose":1.75,"preHourTrading":{"tag":"盘前","latestPrice":1.77,"preClose":1.75,"latestTime":"07:00 EDT","volume":30001,"amount":53101.7730001,"timestamp":1777892438558,"change":0.02,"changeRate":0.011429,"amplitude":0.001257},"postHourTrading":{"tag":"盘后","latestPrice":1.74,"preClose":1.75,"latestTime":"19:32 EDT","volume":2797,"amount":4870.9522,"timestamp":1777678342753,"change":-0.01,"changeRate":-0.005714,"amplitude":0.017143},"volumeRatio":2.7629946425280467,"impliedVol":5.0063,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/PEPG/tweets","defaultTab":"tweets","newsList":[{"id":"2624515274","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515274?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:40","pubTimestamp":1775047208,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Praxis Precision Medicines (PRAX), PepGen Inc. (PE...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-pepgen-inc-pepg-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-pepgen-inc-pepg-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0029874061.USD","LU0889565916.HKD","BK4581","IE0002141913.USD","IE00BFTCPJ56.SGD","PEPG","OMER","IE0009355771.USD","LABU","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0320765992.SGD","HCSG","BK4585","LU0109394709.USD","IE00BJT1NW94.SGD","LU0128526141.USD","XBI","PRAX","BK4007","XLV","BK4588","IE00BJJMRZ35.SGD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624532138","title":"PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2624532138","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624532138?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:45","pubTimestamp":1774986303,"startTime":"0","endTime":"0","summary":"PepGen  shares fell about 59% in Tuesday trading after the company reported data from the lowest-dose cohort of its ongoing phase 2 FREEDOM2 study evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1.In patients treated at 5 mg/kg, mean splicing correction was 7.3% versus 6.8% with placebo, the company said late Monday, adding that mean splicing correction was 22.9% after excluding one outlier who exhibited a worsening in splicing correction of 70.8%.PGN-EDODM1 was generally well tolerated, with no serious adverse events, according to a statement.The company said dosing continues in the 10 mg/kg multiple ascending dose cohort, with data expected in the second half of 2026. Current cash should fund operations into the second half of 2027, it added.Price: 1.76, Change: -2.47, Percent Change: -58.39","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623538514","title":"PepGen Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2623538514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623538514?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:41","pubTimestamp":1774968060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PEPG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:41 ET (14:41 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623744586","title":"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623744586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623744586?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958444,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA) wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","LU0128526141.USD","BK4137","LABU","XBI","LU0029874061.USD","XLV","PEPG","BK4585","BK4581","BK4588","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623358685","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2623358685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623358685?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:40","pubTimestamp":1774957247,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) stock was down 42% pre-bell Tuesday, adding to losses from the previous session.CDT Equity (CDT) shares were 29% lower, reversing from Monday's gains.T1 Energy (TE) stock was down 17% after the company reported Q4 financial results that trailed analysts' estimates.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TE","BK7104","PEPG","CDT.AU","BK4096","BK4139","BK4121","CDT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585439","title":"Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585439","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585439?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:29","pubTimestamp":1774956562,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) has an average rating of buy and mean price target of $10.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623758532","title":"Stifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623758532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623758532?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:16","pubTimestamp":1774955813,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on PepGen Inc., with a price target of $12.00. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623279373","title":"Stocks to Watch: PepGen, Phreesia, Virgin Galactic","url":"https://stock-news.laohu8.com/highlight/detail?id=2623279373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623279373?lang=en_us&edition=fundamental","pubTime":"2026-03-31 07:05","pubTimestamp":1774911900,"startTime":"0","endTime":"0","summary":"PepGen reported mixed results for its trial of a muscle-disorder treatment. Shares fell 42% to $2.44 in after-hours trading Monday.Phreesia cut its fiscal year 2027 revenue guidance. The stock slid 23% to $8.80 after the bell.Virgin Galactic narrowed its loss in the fourth quarter. Shares rose 9% to $2.37.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG","SPCE","BK4167","BK4187","BK4562","PHR","BK4564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623322872","title":"PepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2623322872","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623322872?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:09","pubTimestamp":1774908540,"startTime":"0","endTime":"0","summary":"PepGen shares fell after the company shared mixed results for its muscle-disorder treatment.The stock slid 48% to $2.20 in after-hours trading Monday. Shares are down 35% this year.PepGen shared results of a trial of patients with myotonic dystrophy type 1, a disorder that causes muscle weakness. The trial measured improvements in restoring normal RNA splicing in muscle tissue among patients.Patients taking 5 mg/kg of PGN-EDODM1 showed a mean splicing correction of 7.3%, just above the 6.8% in placebo-treated patients, PepGen said.The mean splicing correction rate among treated patients was weighed down by one patient, who had a worsening in splicing correction while taking the drug. The patient showed 70.8% worsening in splicing correction, dragging the group's average splicing correction down from 22.9%.No meaningful improvements were observed in a 10-meter walk/run test or in handgrip strength.PepGen does believe the total safety and efficacy results support the potential of the ong","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"PepGen Shares Fall on Mixed Trial Results for Muscle Disorder Drug","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623045324","title":"PepGen down 46% at $2.30 after Phase 2 Freedom trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2623045324","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623045324?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:56","pubTimestamp":1774907764,"startTime":"0","endTime":"0","summary":"17:50 EDT PepGen (PEPG) down 46% at $2.30 after Phase 2 Freedom trial data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-down-46-at-2-30-after-phase-2-freedom-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-down-46-at-2-30-after-phase-2-freedom-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329984","title":"PepGen reports ‘promising’ topline results from MAD cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329984","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329984?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:20","pubTimestamp":1774902005,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) announced promising clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-reports-promising-topline-results-from-mad-cohort-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-reports-promising-topline-results-from-mad-cohort-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623232996","title":"PepGen Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2623232996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623232996?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:07","pubTimestamp":1774901274,"startTime":"0","endTime":"0","summary":"16:01 EDT PepGen (PEPG) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326043","title":"PepGen says Phase 2 FREEDOM2 DM1 trial shows favorable safety at 5 mg/kg dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326043","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326043?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:07","pubTimestamp":1774901221,"startTime":"0","endTime":"0","summary":"PepGen released topline results from 5 mg/kg multiple-ascending-dose cohort in Phase 2 FREEDOM2 study of PGN-EDODM1 in myotonic dystrophy type 1.Trial showed generally favorable tolerability with no serious safety findings reported.Biomarker readouts suggested a signal of activity, with mixed results across patients.Functional assessments showed limited evidence of improvement at this dose.Data from ongoing 10 mg/kg cohort is expected in 2H 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL51jPBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326768","title":"PepGen Inc - Pgn-Edodm1 Well-Tolerated With No Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326768?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA2N4J2K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326722","title":"PepGen Announces Topline Results From Lowest Dose (5 Mg/Kg) Mad Cohort in the Ongoing Phase 2 Freedom2 Study Demonstrating Favorable Safety, Splicing and Vhot Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326722?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA2N4J2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326710","title":"PepGen Inc - on Track to Report 10 Mg/Kg Cohort Data in 2H 2026; Cash Runway Into 2H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326710?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA2N4J2K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326268","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326268","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326268?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:01","pubTimestamp":1774900860,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nAQN2LSHL0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703782","title":"Wedbush Sticks to Its Buy Rating for PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703782?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:18","pubTimestamp":1774268329,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on PepGen Inc. today and set a price target of $9.00. In addition to Wedbush, PepGen Inc. also received a B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617578879","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617578879?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:02","pubTimestamp":1772737341,"startTime":"0","endTime":"0","summary":"Distribution Solutions Group  reported Thursday Q4 adjusted earnings below estimates, and sales also missed the forecast.Shares slumped 27% following an increase in intraday trading volume to over 252,000 from a daily average of about 76,000.Grocery Outlet's  shares sank 26% after the company reported overnight fiscal 2026 adjusted earnings and revenue guidance that trailed analysts' estimates.More than 10.3 million shares of the company traded intraday compared with a daily average of about 2.48 million.PepGen  said late Wednesday that the US Food and Drug Administration placed a partial clinical hold on the phase 2 trial of PGN-EDODM1 for the potential treatment of myotonic dystrophy type 1, a multisystem disorder that affects skeletal and smooth muscle.Shares dropped 18%, with intraday trading volume at over 2.55 million versus a daily average of roughly 652,000.Price: 21.75, Change: -7.96, Percent Change: -26.79","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4104","PEPG","GO","BK4113","LU0385154629.USD","LU0471298777.SGD","DSGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617568521","title":"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568521?lang=en_us&edition=fundamental","pubTime":"2026-03-05 23:50","pubTimestamp":1772725807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG – Research Report) and Compass The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","BK4585","XLV","BK4139","HCSG","LABU","XBI","PEPG","BK4588","LU0128526141.USD","CMPX","BK4137"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pepgen.com","stockEarnings":[{"period":"1week","weight":0.1364},{"period":"1month","weight":0.0057},{"period":"3month","weight":-0.6589},{"period":"6month","weight":-0.6245},{"period":"1year","weight":0.1905},{"period":"ytd","weight":-0.7312}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.057082},{"month":2,"riseRate":0.75,"avgChangeRate":0.580465},{"month":3,"riseRate":0,"avgChangeRate":-0.400307},{"month":4,"riseRate":0.5,"avgChangeRate":0.028304},{"month":5,"riseRate":0.5,"avgChangeRate":0.079881},{"month":6,"riseRate":0,"avgChangeRate":-0.194547},{"month":7,"riseRate":0.5,"avgChangeRate":-0.062921},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102699},{"month":9,"riseRate":0.25,"avgChangeRate":0.658187},{"month":10,"riseRate":0.75,"avgChangeRate":0.035806},{"month":11,"riseRate":0.5,"avgChangeRate":0.080021},{"month":12,"riseRate":0.5,"avgChangeRate":0.010709}],"exchange":"NASDAQ","name":"PepGen Inc.","nameEN":"PepGen Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PepGen Inc.,PEPG,PepGen Inc.股票,PepGen Inc.股票老虎,PepGen Inc.股票老虎国际,PepGen Inc.行情,PepGen Inc.股票行情,PepGen Inc.股价,PepGen Inc.股市,PepGen Inc.股票价格,PepGen Inc.股票交易,PepGen Inc.股票购买,PepGen Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}